Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press52110.17650/1726-9776-2015-11-4-24-33DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиCurrent treatment approach to non-clear cell renal carcinomaСовременные возможности лечения несветлоклеточного почечно-клеточного ракаTsimafeyeuI. V.ТимофеевИ. В.
Russian Federation

Kidney Cancer Research Bureau,

2 Mayakovskogo pereulok, Moscow, 109147

Бюро по изучению рака почки, 

109147, Москва, пер. Маяковского, 2

office@kidneytumor.orgRussian society of clinical oncologyРоссийское общество клинической онкологии3012201511424331012201510122015https://oncourology.abvpress.ru/oncur/article/view/521

Non-clear cell renal cell carcinoma has various histologic subtypes. Tumor biology plays significant role in the disease development. However, despite the one surgical approach both to clear cell and non-clear cell renal carcinoma, patients’ outcomes within one stage of the disease may vary. Furthermore, tumor sensitivity and its response to therapy are highly dependent on the same histologic subtype.

The article gives detailed data on the current treatment of papillary, chromophobe and other histologic subtypes of renal cell carcinoma.

Несветлоклеточный почечно-клеточный рак представлен несколькими гистологическими вариантами. Биология опухоли существенно влияет на течение заболевания. Несмотря на единство хирургического лечения светлоклеточного и несветлоклеточного рака почки, прогноз пациентов с формально одинаковыми стадиями может отличаться. Чувствительность опухоли к лекарственной терапии также зависит от гистологического подтипа. В статье подробно рассматриваются современные возможности лечения папиллярного, хромофобного и других видов почечно-клеточного рака.

non-clear cell renal cell carcinomaclassificationprognosissurgerytargeted therapyнесветлоклеточный почечно-клеточный ракклассификацияпрогнозхирургическое лечениетаргетная терапия1. Алексеев Б.Я., Анжиганова Ю.В., Лыков А.В. и др. Особенности диагностики и лечения рака почки в России: предварительные результаты многоцентрового кооперированного исследования. Онкоурология 2012;(3):24–30. [Alekseyev B.Ya., Anzhiganova Yu.V., Lykov A.V. et al. Some specific features of the diagnosis and treatment of kidney cancer in Russia: preliminary results of a multicenter cooperative study. Onkourologiya = Oncourology 2012;(3):24–30. (In Russ.)].Алексеев Б.Я., Анжиганова Ю.В., Лыков А.В. и др. Особенности диагностики и лечения рака почки в России: предварительные результаты многоцентрового кооперированного исследования. Онкоурология 2012;(3):24–30. [Alekseyev B.Ya., Anzhiganova Yu.V., Lykov A.V. et al. Some specific features of the diagnosis and treatment of kidney cancer in Russia: preliminary results of a multicenter cooperative study. Onkourologiya = Oncourology 2012;(3):24–30. (In Russ.)].2. Tsimafeyeu I., Aksel E. Renal cell carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1–4.Tsimafeyeu I., Aksel E. Renal cell carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1–4.3. Srigley J.R., Delahunt B., Eble J.N., Egevad L. et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 2013;37(10):1469–89.Srigley J.R., Delahunt B., Eble J.N., Egevad L. et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 2013;37(10):1469–89.4. Moch H., Artibani W., Delahunt B. et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009;56(4):636–43.Moch H., Artibani W., Delahunt B. et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009;56(4):636–43.5. Yamashita S., Ioritani N., Oikawa K. et al. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis. Int J Urol 2007;14(8):679–83.Yamashita S., Ioritani N., Oikawa K. et al. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis. Int J Urol 2007;14(8):679–83.6. Winters B.R., Gore J.L., Holt S.K. et al. Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol 2015 Aug 26. pii: S1078-1439(15)00360-9.Winters B.R., Gore J.L., Holt S.K. et al. Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol 2015 Aug 26. pii: S1078-1439(15)00360-9.7. Lughezzani G., Jeldres C., Isbarn H. et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182(4):1287–93.Lughezzani G., Jeldres C., Isbarn H. et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182(4):1287–93.8. Iacovelli R., Modica D., Palazzo A. et al. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J 2015;9(3–4):172–7.Iacovelli R., Modica D., Palazzo A. et al. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J 2015;9(3–4):172–7.9. Steffens S., Janssen M., Roos F.C. et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer 2012;48(15):2347–52.Steffens S., Janssen M., Roos F.C. et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer 2012;48(15):2347–52.10. Bratslavsky G., Boris R.S. Emerging strategies of nephron sparing surgery in patients with localized and recurrent renal cell carcinoma. Malign Tumours 2010;1:5–14.Bratslavsky G., Boris R.S. Emerging strategies of nephron sparing surgery in patients with localized and recurrent renal cell carcinoma. Malign Tumours 2010;1:5–14.11. van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephronsparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52.van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephronsparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52.12. Roos F.C., Steffens S., Junker K. et al. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014;14:372.Roos F.C., Steffens S., Junker K. et al. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014;14:372.13. Zargar-Shoshtari K., Sharma P., Espiritu P. et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol 2015;33(3):112.e23–9.Zargar-Shoshtari K., Sharma P., Espiritu P. et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol 2015;33(3):112.e23–9.14. Abel E.J., Margulis V., Bauman T.M. et al. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus; a contemporary multicenter analysis. BJU Int 2015. doi: 10.1111/bju.13268.Abel E.J., Margulis V., Bauman T.M. et al. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus; a contemporary multicenter analysis. BJU Int 2015. doi: 10.1111/bju.13268.15. Tilki D., Nguyen H.G., Dall'Era M.A. et al. Impact of histologic subtype on cancerspecific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 2014;66(3):577–83.Tilki D., Nguyen H.G., Dall'Era M.A. et al. Impact of histologic subtype on cancerspecific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 2014;66(3):577–83.16. Padrik P. Treatment of non-clear cell renal carcinoma. Malign Tumours 2010;1:35–8. doi: 10.18027/2224-5057-2011-1-40-44.Padrik P. Treatment of non-clear cell renal carcinoma. Malign Tumours 2010;1:35–8. doi: 10.18027/2224-5057-2011-1-40-44.17. Motzer R.J., Bacik J., Schwarz L. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–63.Motzer R.J., Bacik J., Schwarz L. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–63.18. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81.Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81.19. Kroeger N., Xie W., Lee J.L., Bjarnason G.A. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119(16):2999–3006.Kroeger N., Xie W., Lee J.L., Bjarnason G.A. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119(16):2999–3006.20. Волкова М.И., Климов А.В. Роль паллиативной нефрэктомии в лечении диссеминированного рака почки в эру таргетной терапии. Злокачественные опухоли 2012;2(2):58–60. [Volkova M.I., Klimov A.V. The role of palliative nephrectomy for metastatic renal cell carcinoma in the era of targeted agents. Malignant tumours 2012;2(2):58–60. (In Russ.)].Волкова М.И., Климов А.В. Роль паллиативной нефрэктомии в лечении диссеминированного рака почки в эру таргетной терапии. Злокачественные опухоли 2012;2(2):58–60. [Volkova M.I., Klimov A.V. The role of palliative nephrectomy for metastatic renal cell carcinoma in the era of targeted agents. Malignant tumours 2012;2(2):58–60. (In Russ.)].21. Tsimafeyeu I., Zart J.S., Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. BJU International 2013;112 (1):32–8.Tsimafeyeu I., Zart J.S., Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. BJU International 2013;112 (1):32–8.22. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65.Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65.23. Tsimafeyeu I., Snegovoy A., Varlamov S. et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol 2015;10(3):423–7.Tsimafeyeu I., Snegovoy A., Varlamov S. et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol 2015;10(3):423–7.24. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2016.NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2016.25. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014;25 Suppl 3:iii49–56.Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014;25 Suppl 3:iii49–56.26. Dutcher J.P., de Souza P., McDermott D. et al. Effect of temsirolimus versus interferonalpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202–9.Dutcher J.P., de Souza P., McDermott D. et al. Effect of temsirolimus versus interferonalpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202–9.27. Tannir N.M., Jonasch E., Altinmakas E. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 2014;32:5 (suppl; abstr 4505).Tannir N.M., Jonasch E., Altinmakas E. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 2014;32:5 (suppl; abstr 4505).28. Armstrong A.J., Broderick S., Eisen T. et al. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 2015;33 (suppl; abstr 4507).Armstrong A.J., Broderick S., Eisen T. et al. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 2015;33 (suppl; abstr 4507).29. Escudier B.J., Bracarda S., Rey J.P. et al. Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology. J Clin Oncol 2014;32 (suppl 4; abstr 410).Escudier B.J., Bracarda S., Rey J.P. et al. Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology. J Clin Oncol 2014;32 (suppl 4; abstr 410).30. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients. J Clin Oncol 2009;7(22):3584–90.Motzer R.J., Hutson T.E., Tomczak P. et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients. J Clin Oncol 2009;7(22):3584–90.31. Иванов С.А., Клименко А.А., Добровольская Н.Ю. Длительное применение бевацизумаба с интерфероном альфа в качестве первой линии таргетной терапии распространенного рака почки. Злокачественные опухоли 2014;2(9):37–42. [Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Long-term treatment of bevacizumab combined with interpheron alpfa in the first-line targeted therapy for metastatic renal cell carcinoma. Malignant tumours 2014;2(9):37–42. (In Russ.)].Иванов С.А., Клименко А.А., Добровольская Н.Ю. Длительное применение бевацизумаба с интерфероном альфа в качестве первой линии таргетной терапии распространенного рака почки. Злокачественные опухоли 2014;2(9):37–42. [Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Long-term treatment of bevacizumab combined with interpheron alpfa in the first-line targeted therapy for metastatic renal cell carcinoma. Malignant tumours 2014;2(9):37–42. (In Russ.)].32. Koh Y., Lim H.Y., Ahn J.H. et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013;24(4):1026–31.Koh Y., Lim H.Y., Ahn J.H. et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013;24(4):1026–31.33. Hutson T.E., Escudier B., Esteban E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(8):760–7.Hutson T.E., Escudier B., Esteban E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(8):760–7.34. Schrader A.J., Seseke S., Keil C. et al. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer. Eur Urol 2014;66(2):275–81.Schrader A.J., Seseke S., Keil C. et al. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer. Eur Urol 2014;66(2):275–81.35. Каприн А.Д., Иванов С.А., Клименко А.А., Добровольская Н.Ю. Пример применения ингибитора тирозинкиназ в качестве таргетной терапии при светлоклеточном варианте рака почки. Злокачественные опухоли 2015;1(12):49–52. [Kaprin A.D., Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Example of the first-line targeted therapy with tyrosine kinase inhibitor in the treatment of clear cell renal cell carcinoma. Malignant tumours 2015;1(12):49–52. (In Russ.)].Каприн А.Д., Иванов С.А., Клименко А.А., Добровольская Н.Ю. Пример применения ингибитора тирозинкиназ в качестве таргетной терапии при светлоклеточном варианте рака почки. Злокачественные опухоли 2015;1(12):49–52. [Kaprin A.D., Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Example of the first-line targeted therapy with tyrosine kinase inhibitor in the treatment of clear cell renal cell carcinoma. Malignant tumours 2015;1(12):49–52. (In Russ.)].36. Tsimafeyeu I., Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res Ther 2010;6(4):575–7.Tsimafeyeu I., Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res Ther 2010;6(4):575–7.37. Česas A., Mikutaitė V. Successful Treatment of metastatic renal cell carcinoma with sunitinib. Malign Tumours 2010;1:39–40.Česas A., Mikutaitė V. Successful Treatment of metastatic renal cell carcinoma with sunitinib. Malign Tumours 2010;1:39–40.38. Gore M.E., Szczylik C., Porta C. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113(1):12–9.Gore M.E., Szczylik C., Porta C. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113(1):12–9.39. Ravaud A., Oudard S., De Fromont M. et al. First line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP - a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). Ann Oncol 2012;23(suppl 9):ix258–ix293.Ravaud A., Oudard S., De Fromont M. et al. First line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP - a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). Ann Oncol 2012;23(suppl 9):ix258–ix293.40. Lee J.L., Ahn J.H., Lim H.Y. et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23(8):2108–14.Lee J.L., Ahn J.H., Lim H.Y. et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23(8):2108–14.41. Bilen M.A., Zurita A.J., Ilias-Khan N.A. et al. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: results from a phase II trial. Oncologist 2015;20(10):1140–8.Bilen M.A., Zurita A.J., Ilias-Khan N.A. et al. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: results from a phase II trial. Oncologist 2015;20(10):1140–8.42. Tannir N.M., Plimack E., Ng C. et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62(6):1013–9.Tannir N.M., Plimack E., Ng C. et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62(6):1013–9.43. Stadler W.M., Figlin R., McDermott D. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272–80.Stadler W.M., Figlin R., McDermott D. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272–80.44. Stadler W.M., Figlin R.A., Ernstoff M.S. et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with nonclear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2007;25(18): suppl 5036.Stadler W.M., Figlin R.A., Ernstoff M.S. et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with nonclear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2007;25(18): suppl 5036.45. Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011;22(8):1812–23.Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011;22(8):1812–23.46. Jäger D., Ma J.H., Mardiak J. et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer 2015;13(2): 156–64.Jäger D., Ma J.H., Mardiak J. et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer 2015;13(2): 156–64.47. Gordon M.S., Hussey M., Nagle R.B. et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27(34):5788–93.Gordon M.S., Hussey M., Nagle R.B. et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27(34):5788–93.48. Iyevleva A.G., Novik A.V., Moiseyenko V.M., Imyanitov E.N. EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol 2009;27(5):548–50.Iyevleva A.G., Novik A.V., Moiseyenko V.M., Imyanitov E.N. EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol 2009;27(5):548–50.49. Владимирова Л.Ю., Абрамова Н.А., Шихлярова А.И. Метаболическая модуляция противоопухолевого эффекта цитостатиков в эксперименте и клинике. Злокачественные опухоли 2014;3(10):42–7. [Vladimirova L.U., Abramova N.A., Shihlyarova A.I. Metabolic modulation of the antitumor cytostatic activity in vitro and in vivo. Malignant tumours 2014;3(10):42–7. (In Russ.)].Владимирова Л.Ю., Абрамова Н.А., Шихлярова А.И. Метаболическая модуляция противоопухолевого эффекта цитостатиков в эксперименте и клинике. Злокачественные опухоли 2014;3(10):42–7. [Vladimirova L.U., Abramova N.A., Shihlyarova A.I. Metabolic modulation of the antitumor cytostatic activity in vitro and in vivo. Malignant tumours 2014;3(10):42–7. (In Russ.)].50. Насхлеташвили Д.Р. Cовременные возможности лекарственной терапии больных раком почки с метастатическим поражением головного мозга. Злокачественные опухоли 2012;2(2):61–7. [Naskhletashvili D.R. Current therapeutic approaches in renal cell cancer patients with brain metastases. Malignant tumours 2012;2(2):61–7.(In Russ.)].Насхлеташвили Д.Р. Cовременные возможности лекарственной терапии больных раком почки с метастатическим поражением головного мозга. Злокачественные опухоли 2012;2(2):61–7. [Naskhletashvili D.R. Current therapeutic approaches in renal cell cancer patients with brain metastases. Malignant tumours 2012;2(2):61–7.(In Russ.)].51. Tsimafeyeu I., Demidov L., Kharkevich G. et al. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol 2012;35:251–4.Tsimafeyeu I., Demidov L., Kharkevich G. et al. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol 2012;35:251–4.52. Oudard S., Banu E., Vieillefond A. et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007;177:1698–702.Oudard S., Banu E., Vieillefond A. et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007;177:1698–702.53. Bylow K., Atkins M., Posadas E. et al. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009;7:39–42.Bylow K., Atkins M., Posadas E. et al. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009;7:39–42.54. Richey S.L., Tamboli P., Ng C.S. et al. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2013;36(5):450–4.Richey S.L., Tamboli P., Ng C.S. et al. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2013;36(5):450–4.55. Федянин М.Ю. Персонализированная терапия в онкологии: настоящее и будущее. Злокачественные опухоли 2012;8(3):24–30. [Fedyanin M.U. Personalized medicine in oncology: current and future. Malignant tumours 2012;8(3):24–30. (In Russ.)].Федянин М.Ю. Персонализированная терапия в онкологии: настоящее и будущее. Злокачественные опухоли 2012;8(3):24–30. [Fedyanin M.U. Personalized medicine in oncology: current and future. Malignant tumours 2012;8(3):24–30. (In Russ.)].56. Golovine K., Makhov P., Naito S. et al. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 2015;16(5):743–9.Golovine K., Makhov P., Naito S. et al. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 2015;16(5):743–9.57. Tsimafeyeu I., Wynn N., Gordiyev M., Khasanova A. FGFR2 expression and mutation are rare in papillary renal cell carcinoma [abstr]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl): abstr 4069. doi:10.1158/1538-7445.AM2013-4069.Tsimafeyeu I., Wynn N., Gordiyev M., Khasanova A. FGFR2 expression and mutation are rare in papillary renal cell carcinoma [abstr]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl): abstr 4069. doi:10.1158/1538-7445.AM2013-4069.58. Atkins M.B., Gravis G., Drosik K. et al. Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-label, multicenter, phase II study. J Clin Oncol 2015 [epub ahead of print]. doi: 10.1200/JCO.2014.60.6012.Atkins M.B., Gravis G., Drosik K. et al. Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-label, multicenter, phase II study. J Clin Oncol 2015 [epub ahead of print]. doi: 10.1200/JCO.2014.60.6012.